Psychiatry research case reports最新文献_第5页

Exploring Neuropsychiatric Sequelae Arising from Complications of Serotonin Syndrome: A Case Report 探讨血清素综合征并发症引起的神经精神后遗症：1例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-09-16 DOI: 10.1016/j.psycr.2025.100290

Arul Sangani , Pegah Yakhchalian , Kimia Mondegari , Olivia Erickson , Fahad Molla

引用次数: 0

Retraction notice to “COVID-19-induced new-onset psychosis: a case report” [Psychiatry Research Case Reports, Volume 1, Issue 2, December 2022, 100048] 《新冠肺炎致新发精神病1例报告》撤稿通知[精神病学研究病例报告，第1卷第2期，2022年12月，100048]

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-06-24 DOI: 10.1016/j.psycr.2025.100263

Xiaoyi Gao, Noam Grysman, Mirela Marcu

引用次数: 0

Complete resolution of urge urinary incontinence following treatment of ADHD with lisdexamfetamine: a case report 完全解决急迫性尿失禁后治疗ADHD：一个案例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-08-25 DOI: 10.1016/j.psycr.2025.100284

Adem T. Can , Jim Lagopoulos

引用次数: 0

Clozapine withdrawal syndrome; a case report 氯氮平戒断综合征；病例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-07-23 DOI: 10.1016/j.psycr.2025.100279

Alonso Elías Garrido-Pinzás , Marcelo Cruzalegui , Cynthia Cabrejos Novoa

引用次数: 0

Rapid-onset black hairy tongue following clomipramine initiation and rechallenge: A case report 氯丙咪嗪启动和重新挑战后快速发作的黑毛舌：1例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-09-09 DOI: 10.1016/j.psycr.2025.100289

Daniele Cavaleri , Filippo Fabio Barbieri , Alessandra Bartoccetti , Massimiliano Manzato , Marco Otto Maria Toscano , Giuseppe Carrà , Francesco Bartoli

{"title":"Rapid-onset black hairy tongue following clomipramine initiation and rechallenge: A case report","authors":"Daniele Cavaleri , Filippo Fabio Barbieri , Alessandra Bartoccetti , Massimiliano Manzato , Marco Otto Maria Toscano , Giuseppe Carrà , Francesco Bartoli","doi":"10.1016/j.psycr.2025.100289","DOIUrl":"10.1016/j.psycr.2025.100289","url":null,"abstract":"<div><div>Black hairy tongue (BHT), a benign condition characterized by hypertrophy of the filiform papillae and discoloration of the dorsal tongue, is commonly associated with antibiotic use, poor oral hygiene, lifestyle factors, and general health issues. By contrast, psychotropic drug-induced BHT is rare and typically emerges weeks to months after treatment initiation. We report the case of a 42-year-old male patient with recurrent major depressive disorder and prior use of different psychotropic medications who developed BHT within days of initiating clomipramine on two separate occasions. In the first trial, BHT resolved shortly after clomipramine discontinuation. On the second occasion, considering the effectiveness of the treatment, the absence of concerning symptoms, and the exclusion of other causes through multidisciplinary evaluation, the patient remained on clomipramine. Despite oral hygiene measures, BHT persisted. Close temporal association, reproducibility upon re-challenge, resolution upon discontinuation during the first trial, and absence of alternative explanations supported a definite causal link, as indicated by the Expanded Naranjo Adverse Drug Reaction Probability Scale. Chronic smoking and prolonged chlorhexidine mouthwash use may have contributed, though these were unlikely the individual causes. To our knowledge, this is the first report of clomipramine-induced BHT with such rapid onset and recurrence. This case highlights the importance of recognizing BHT as a potential early-onset side effect of tricyclic antidepressants, particularly clomipramine. Prompt recognition, interdisciplinary assessment, and consideration of the risk-benefit balance are essential. Although an idiosyncratic reaction – independent of clomipramine-induced xerostomia – can be hypothesized, further research is needed to clarify the mechanisms underlying antidepressant-induced BHT.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100289"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cariprazine for hyperactive delirium in a medically complex ICU Patient: A case report 卡吡嗪治疗重症监护病房复杂病人的多动性谵妄1例

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-09-04 DOI: 10.1016/j.psycr.2025.100286

Ibrahim Abdulrahman Alsuwailem , Abdullah Alsubhi , Lama Faiz Aljuaid

{"title":"Cariprazine for hyperactive delirium in a medically complex ICU Patient: A case report","authors":"Ibrahim Abdulrahman Alsuwailem , Abdullah Alsubhi , Lama Faiz Aljuaid","doi":"10.1016/j.psycr.2025.100286","DOIUrl":"10.1016/j.psycr.2025.100286","url":null,"abstract":"<div><h3>Background</h3><div>Hyperactive delirium is a dangerous and under-studied complication in critically ill patients. Management is often complicated by QTc (corrected QT interval) prolongation associated with standard antipsychotics. Cariprazine, a dopamine D₂/D₃ partial agonist with minimal cardiac risk, may offer an alternative, though its role in delirium remains unexplored. Emerging real-world evidence supports cariprazine’s use in treatment-resistant psychiatric conditions, providing indirect support for its consideration in medically complex patients (Martiadis et al., 2024)</div></div><div><h3>Case Presentation</h3><div>A 33-year-old male with end-stage renal disease, sepsis, and prolonged QTc developed severe hyperactive delirium during an ICU admission. Despite trials of olanzapine (Zyprexa), lorazepam (2 mg IV q6h), and haloperidol (5 mg IV q6h), his agitation persisted. He required intubation for safety and sedation. Supportive care included dialysis, broad-spectrum antibiotics, oxygen supplementation (nasal cannula, high-flow, then intubation), IV fluids, and enteral feeding. Psychiatry was re-consulted on June 3 and confirmed hyperactive delirium. On June 4, cariprazine 1.5 mg was administered via NG tube (capsule powder dissolved in 30 mL water). Within 48–72 h, his behavior improved, coinciding with correction of metabolic derangements, resolution of sepsis, and stabilization of renal function. He was successfully extubated and discharged psychiatrically and medically stable.</div></div><div><h3>Conclusion</h3><div>This case suggests that cariprazine may be a potential alternative in ICU patients with hyperactive delirium and QTc concerns. However, clinical improvement was multifactorial, reflecting both psychiatric pharmacotherapy and comprehensive ICU management. This single case highlights the importance of multidisciplinary care and should be considered hypothesis-generating.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100286"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction notice to “Exploring the Risk of Magnesium Use for Antipsychotic Induced Constipation: A Case study for consideration” [Psychiatry Research Case Reports Volume 2, Issue 1, June 2023, 100132] “探索镁用于抗精神病药物引起的便秘的风险：一个案例研究”的撤回通知[精神病学研究病例报告第2卷，第1期，2023年6月，100132]

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-08-07 DOI: 10.1016/j.psycr.2025.100277

TammieLee Demler , TammieLee Demler , Samara White

引用次数: 0

Retraction notice to “Diagnosis of unsuspected catatonia with an inadvertent lorazepam challenge test” [Volume 1, Issue 2, December 2022, 100073] 撤回“用无意的劳拉西泮激发试验诊断未怀疑的紧张症”的通知[第1卷，第2期，2022年12月，100073]

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-07-23 DOI: 10.1016/j.psycr.2025.100272

Ila Gautham , Annise Wilson

引用次数: 0

Retraction notice to “Pseudocyesis in a deployed military member” [Psychiatry Research Case Reports Volume 2, Issue 2, December 2023, 100183] 关于“一名派驻军人的伪作”的撤回通知[精神病学研究病例报告第2卷第2期，2023年12月，100183]

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-07-22 DOI: 10.1016/j.psycr.2025.100275

Ezie Nguyen , Allison Watkins , Lauren Wells

引用次数: 0

The feasibility and acceptability of metacognitive therapy in a forensic setting: a case report of chronic paranoid schizophrenia with persistent depressive symptoms 元认知疗法在法医环境中的可行性和可接受性：慢性偏执型精神分裂症伴持续抑郁症状的病例报告

Psychiatry research case reports Pub Date : 2025-12-01 Epub Date: 2025-08-07 DOI: 10.1016/j.psycr.2025.100282

Riitta Kuokkanen

{"title":"The feasibility and acceptability of metacognitive therapy in a forensic setting: a case report of chronic paranoid schizophrenia with persistent depressive symptoms","authors":"Riitta Kuokkanen","doi":"10.1016/j.psycr.2025.100282","DOIUrl":"10.1016/j.psycr.2025.100282","url":null,"abstract":"<div><div>There is increasing evidence that metacognitive therapy (MCT; Wells, 2009) results in significant benefits in various disorders, including depression and psychosis, and may even surpass the efficacy of cognitive behavioral therapy (CBT), currently recommended in treatment guidelines. The implementation of advanced new forms of treatment, and especially research into the effectiveness of these new treatments, is often more challenging in forensic psychiatric treatment and with difficult-to-treat patients. The evidence on the effectiveness of psychological interventions in this population is still limited and research on MCT in this context is non-existent. As a first step in evaluating MCT’s feasibility and acceptability in this context, this paper describes a case example of the treatment of persistent depressive symptoms of chronic paranoid schizophrenia augmented with MCT in a forensic mental health setting. In addition to treatment as usual, i.e. medication, regular conversations with a designated nurse, and a social skills group, 18 weekly sessions of MCT following a depression treatment plan, targeting rumination/worry, attentional control, metacognitive beliefs, and dysfunctional behaviors, were delivered. The same person conducted the assessments and therapy. Clinically significant reductions in depressive symptoms and delusions were observed, assessed at pre- and post-therapy. In addition, a prominent decline in rumination, dysfunctional metacognitive beliefs and coping behaviors took place. Although the specific contribution of MCT cannot be established, it is concluded that MCT may be a useful supplement to treatment options in the treatment of difficult-to-treat patients and in a forensic setting.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 2","pages":"Article 100282"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0